Epstein-Barr Virus Lymphoproliferative Disorders After Liver Transplantation

This is the authors' abstract. We don't add key points for this paper.

Major advances have contributed to the understanding of post-transplant lymphoproliferative disorders (PTLD) in solid organ transplantation in recent years. Risk factors for development of PTLD, methods of diagnosis, and the relationship between PTLD and Epstein-Barr virus (EBV) infection have been well defined. Research efforts have also been directed at the various markers that signal EBV infection and the subsequent potential of developing PTLD. Different therapeutic approaches have also been devised in an effort to treat PTLD once it has been identified. The outcome for the most severe forms of PTLD, however—i.e., polymorphic and monomorphic lymphomas—has continued to be disappointing and associated with high morbidity and mortality. Understanding the pathophysiology and clinical course of the syndrome can result in prevention and treatment of liver transplant patients who are susceptible to and who develop EBV infection or early stages of PTLD.